Figure 2:

Schematic of the physiologically based pharmacokinetic (PBPK) model incorporating metabolism of dibenzo[def,p]chrysene (DBC). We expanded a previously published basic PBPK model for DBC (26) shown in orange, to include a parallel model, shown in blue, describing the disposition of the diol metabolite of DBC. Oral absorption of DBC to a theoretical two-compartment GI tract (GI 1 and GI2) is modeled by selecting appropriate values for absorption parameters (KAS, KAI, KSI; see Table 7 for further details).